Table 4 Clinical and laboratory characteristics and outcome comparing AMAN versus AMSAN subtypes of GBS

Age, years

38 (25–52)

38 (27.25–60.25)

0.34

Sex (men)

25/43 (58.1)

15/28 (53.6)

0.70

Time of antecedent event before symptom onset, days

10 (7–14)

10 (5–14)

0.98

Time from symptom onset to presentation, days

4 (2–7)

7 (2–14)

0.07

Clinical features at admission

 Ophthalmoplegia

1/43 (2.3)

2/25 (8.0)

0.55

 Facial diplegia

14/43 (32.6)

13/25 (52.0)

0.11

 Oropharyngeal weakness

9/43 (20.9)

15/26 (57.7)

0.002

5.2 (1.8–15)

Able to walk independently

11/41 (26.8)

5/27 (18.5)

0.43

Antecedent infection

 URTI

7/38 (18.4)

8/26 (30.8)

0.25

 Diarrhea

22/38 (57.9)

5/26 (19.2)

0.002

5.8 (1.8–18.6)

Investigations

 CSF Protein level, g/L

0.5 (0.32–0.86)

0.93 (0.59–2.4)

0.036*

 CSF protein > 0.45 g/L

20/36 (55.6)

18/21 (85.7)

0.02

4.8 (1.2–19.2)

 Cell count > 5/µl

3/36 (8.3)

0/21 (0.0)

0.30

 Low FVC at admission

7/26 (26.9)

6/13 (46.2)

0.29

Nerve root enhancement on MRI

10/33 (30.3)

6/19 (31.6)

0.94

Hospital course

 Repeated therapy

10/41 (24.4)

13/27 (48.1)

0.043

2.9 (1.02–8.1)

 ICU admission

10/43 (23.3)

20/28 (71.4)

 < 0.001

8.3 (2.8–24.4)

 Mechanical ventilation

9/31 (29.0)

17/27 (63.0)

0.01

4.2 (1.4–12.5)

 Tracheostomy

5/29 (17.2)

12/27 (44.4)

0.03

3.8 (1.1–13.1)

 Duration of ICU stay, days

16 (5–29.25)

33 (20–81)

0.049

Duration of hospitalization, weeks

2 (1–8.5)

12 (3–44)

0.001

Outcome

Able to walk independently at follow-up

27/34 (79.4)

11/19 (57.9)

0.10

Duration of follow-up, months

12.5 (4.6–20.8)

8 (3.5–15.2)

0.23